SteadyMed Raises $30 Million in Private Placement
April 21, 2017 08:10 ET
|
SteadyMed Therapeutics
SteadyMed prepares to file New Drug Application (NDA) for Trevyent® in Q2 2017 Financing provides capital for Trevyent commercial launch preparation SAN RAMON, Calif., April 21, 2017 (GLOBE...
SteadyMed Completes Clinical Validation Study of Trevyent®
April 05, 2017 09:03 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif., April 05, 2017 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and...
SteadyMed Receives Favorable Ruling in Inter Partes Review against United Therapeutics Patent
March 31, 2017 14:18 ET
|
SteadyMed Therapeutics
U.S. Patent Trial and Appeal Board Cancels all claims in United Therapeutics’ ‘393 patent for purification of prostacyclin derivatives, rendering patent invalid. SteadyMed plans to file New Drug...
SteadyMed Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results
March 29, 2017 16:05 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif., March 29, 2017 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and...
SteadyMed Outlines Strategic Goals and Priorities for 2017 and Provides Update on Trevyent Launch Plans
January 09, 2017 08:30 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif., Jan. 09, 2017 (GLOBE NEWSWIRE) -- SteadyMed Therapeutics Ltd. (NASDAQ:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat...
SteadyMed Hires Pulmonary Hypertension Veteran to Lead Patient Advocacy and Community Relations
December 07, 2016 08:30 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif., Dec. 07, 2016 (GLOBE NEWSWIRE) -- SteadyMed Therapeutics Ltd. (NASDAQ:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat...
SteadyMed Provides Update on IPR Hearing
December 05, 2016 08:30 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif., Dec. 05, 2016 (GLOBE NEWSWIRE) -- SteadyMed Therapeutics Ltd. (NASDAQ:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat...
SteadyMed Celebrates Phenomenal People With Pulmonary Hypertension During PH Awareness Month With Launch of New Informational Website and #PHenomSelf Social Media Campaign
November 17, 2016 08:30 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif., Nov. 17, 2016 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY) today announced that it has launched a new website, BePHenomenal.com, dedicated to educating and empowering...
SteadyMed Provides Corporate Update and Reports Third Quarter 2016 Financial Results
November 14, 2016 09:02 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif., Nov. 14, 2016 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and...
SteadyMed to Present at the 25th Annual Credit Suisse Healthcare Conference
October 31, 2016 08:30 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif., Oct. 31, 2016 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and...